Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2024 08:00 ET | Source: Nexalin Technology, Inc.

Nexalin Technology CEO Provides Letter to Shareholders

HOUSTON, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today released a letter to shareholders from its CEO Mark White: Dear...
November 01, 2024 14:00 ET | Source: Nexalin Technology, Inc.

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15...
November 01, 2024 10:34 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market...
October 28, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

HOUSTON, TX, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced publication of a landmark study titled, “Altered...
October 22, 2024 14:15 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Gen-3 Halo Headset Designed to Offer Convenient At-Home Treatment Through Virtual Clinic Model Study to Build on Positive Results from Previous Clinical Trial Treating Veterans with Mild...
October 17, 2024 08:30 ET | Source: Nexalin Technology, Inc.

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

HOUSTON, TX, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced results from a clinical trial demonstrating improvements in...
October 14, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announces the appointment of Carolyn Shelton as Senior Vice President of...
September 05, 2024 09:00 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announced its participation in a high-profile Congressional roundtable in...
July 18, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) --...
July 01, 2024 14:45 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Closing of $5.2 Million Public Offering

HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of...